The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...

Symptomatic drug therapy should be initiated when parkinsonian symptoms become bothersome to the patient. L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated ...

NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...

Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...

NeuroQuiet is an advanced auditory support supplement that takes hearing experience to the next level. It strategically ...

Discover the truth about improved hearing with NeuroQuiet reviews—real experiences, benefits, and results revealed in this ...

Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), which can ...

U of A researchers have uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's drug levodopa.